Catalyst Pharmaceuticals EPS Forecast Jumps to $2.82; Shares Up 22.8%
Catalyst Pharmaceuticals holds a Zacks Rank #1 Strong Buy with 2026 EPS consensus rising from $2.53 to $2.82 over the past 60 days and a current-year revenue estimate of $630.3 million, implying 7% growth. CPRX shares surged 22.8% over six months with an average 35.2% earnings surprise.
1. Consensus Estimate Revisions
Over the past 60 days, the 2026 EPS consensus for Catalyst Pharmaceuticals increased from $2.53 to $2.82 per share. Analysts peg 2026 revenue at $630.3 million, reflecting a projected 7% year-over-year gain.
2. Share Performance and Earnings Surprise
CRPX shares have climbed 22.8% in the last six months, outpacing many peers. The company has beaten earnings estimates in each of the past four quarters, posting an average surprise of 35.2%, underscoring consistent operational execution.
Related News
GOOG
Ackman Cuts Alphabet Stake 95% as Nvidia Forecast Raises Google Cloud Competition
GOOG•
MS
Morgan Stanley to Co-Lead SpaceX’s $1.75T Nasdaq IPO with Four Banks
MS•
GOOGL
Alphabet Executes Record Yen Bond Sale as Google Secures 9.7 GWh AI Storage Contracts
GOOGL•
NVDA
Nvidia Targets $200 Billion Agentic AI Market with Vera CPU Launch
NVDA•
DAO
Youdao Q1 Revenue Rises 3.8% to RMB1.3B, Marketing Jumps 20.9%
DAO•
Sources
FF